The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease

Autor: P. Rutgeerts
Jazyk: angličtina
Rok vydání: 1998
Předmět:
Zdroj: Mediators of Inflammation, Vol 7, Iss 3, Pp 137-140 (1998)
Druh dokumentu: article
ISSN: 0962-9351
1466-1861
DOI: 10.1080/09629359891036
Popis: Glucocorticosteroids are the mainstay of treatment of active Crohn's disease and ulcerative colitis. These drugs however carry important cosmetic short-term side effects and when used long-term they induce severe irreversible complications. Topically acting glucocorticosteroids, especially budesonide, have been designed to achieve local effect at the site of inflammation without systemic effects of the drug. The first results of clinical trials are promising and budesonide has been shown to have an improved safety with almost comparable efficacy in comparison with prednisolone. The optimal enema dose seems to be 2 mg/100 ml at night whereas 9 mg o.m. is the optimal dose to treat ileal or right ileocolonic Crohn's disease. Topically acting GCS, like standard GCS are not effective for maintenance of remission of Crohn's disease or recurrence prevention after resection of the involved Crohn's segment.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje